Tag Archives: OncoMed

September, 2018

April, 2017

  • 17 April

    OncoMed’s Tarextumab Misses Primary Endpoint in Mid-Stage Lung Cancer Trial

    REDWOOD CITY, Calif., April 17, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with …

  • 10 April

    OncoMed’s Demcizumab Misses Primary Endpoint in Mid-Stage Pancreatic Cancer Trial

    REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s Phase 2 YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination with Abraxane® (paclitaxel …

April, 2015